Recombinant erythropoietin (Shanxi Weiqidaguangming)

重组人促红素(山西威奇)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant erythropoietin (Shanxi Weiqidaguangming)
Drug Alias NameCadicrit
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsAnemia
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryMainland China
Original Approved Date1998/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A